nach oben

Clinical and Experimental Medicine

Erschienen in:

01.06.2012 | Original Article

Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients

verfasst von: T. D. Shi, J. M. Zhang, X. F. Wang, M. Chen, H. Sun, C. B. Chen, H. Ren

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

iNKT cells are relatively abundant in the liver, which suggests that they may play important roles in the clearance of invading foreign pathogens such as hepatitis B virus. In this study, we investigated the frequencies, functions and PD-1 expression of peripheral iNKT cells from HBeAg-positive chronic hepatitis B (CHB) patients during antiviral treatment with Telbivudine. Results demonstrated that as compared with the healthy donors, the peripheral iNKT cells from these patients existed at lower frequencies, displayed impaired capabilities to produce IFN-γ and expressed higher PD-1. Antiviral treatment with Telbivudine significantly increased IFN-γ production by iNKT cells, which may be associated with the decreased PD-1 expression as manifested by blocking experiments. Our study suggested that iNKT cells played an important role in the chronicity of HBV infection and antiviral therapy with Telbivudine could restore at least in part the impaired host immune response in the HBeAg-positive CHB patients.

Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what’s in a name? Nat Rev Immunol 4(3):231–237PubMedCrossRef

Van Kaer L (2007) NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 19(3):354–364PubMedCrossRef

Seino K, Taniguchi M (2005) Functionally distinct NKT cell subsets and subtypes. J Exp Med 202(12):1623–1626PubMedCrossRef

Lantz O, Bendelac A (1994) An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4⁺ and CD4⁻ 8− T cells in mice and humans. J Exp Med 180(3):1097–1106PubMedCrossRef

Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278(5343):1626–1629PubMedCrossRef

Tillmann HL, McHutchison JG (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357(25):2576–2588CrossRef

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM et al (2007) Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147(11):745–754PubMed

Emoto M, Kaufmann SH (2003) Liver NKT cells: an account of heterogeneity. Trends Immunol 24(7):364–369PubMedCrossRef

Klugewitz K, Adams DH, Emoto M, Eulenburg K, Hamann A (2004) The composition of intrahepatic lymphocytes: shaped by selective recruitment? Trends Immunol 25(11):590–594PubMedCrossRef

10.

Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192(7):921–930PubMedCrossRef

11.

de Lalla C, Galli G, Aldrighetti L, Romeo R, Mariani M, Monno A et al (2004) Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis. J Immunol 173(2):1417–1425PubMed

12.

Michel ML, Keller AC, Paget C, Fujio M, Trottein F, Savage PB et al (2007) Identification of an IL-17-producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J Exp Med 204(5):995–1001PubMedCrossRef

13.

Yoshiga Y, Goto D, Segawa S, Ohnishi Y, Matsumoto I, Ito S et al (2008) Invariant NKT cells produce IL-17 through IL-23-dependent and -independent pathways with potential modulation of Th17 response in collagen-induced arthritis. Int J Mol Med 22(3):369–374PubMed

14.

Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M et al (2000) The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 12(7):987–994PubMedCrossRef

15.

Moll M, Kuylenstierna C, Gonzalez VD, Andersson SK, Bosnjak L, Sönnerborg A et al (2009) Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 39(3):902–911PubMedCrossRef

16.

Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(3):336–347PubMedCrossRef

17.

Okazaki T, Iwai Y, Honjo T (2002) New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 14(6):779–782PubMedCrossRef

18.

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704PubMedCrossRef

19.

Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H et al (2009) PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells. J Immunol 182(5):2816–2826PubMedCrossRef

20.

Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M et al (2008) Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 181(10):6707–6710PubMed

21.

Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ et al (2010) PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell dependent airway hyperreactivity in opposing directions. Mucosal Immunol 3(1):81–91PubMedCrossRef

22.

Jung MC, Pape GR (2002) Immunology of hepatitis B infection. Lancet Infect Dis 2(1):43–50PubMedCrossRef

23.

Radziewicz H, Hanson HL, Ahmed R, Grakoui A (2008) Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application? Gastroenterology 134(7):2168–2171PubMedCrossRef

24.

Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T et al (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81(8):4215–4225PubMedCrossRef

25.

Maier H, Isogawa M, Freeman GJ, Chisari FV (2007) PD-1: PD-L1 interactions contribute to the functional suppression of virus-specific CD8⁺T lymphocytes in the liver. J Immunol 178(5):2714–2720PubMed

26.

Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z (2008) PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 45(4):963–970PubMedCrossRef

27.

Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2):682–693PubMedCrossRef

28.

Zhang Z, Zhang JY, Wherry EJ, Jin B, Xu B, Zou ZS et al (2008) Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Gastroenterology 134(7):1938–1949PubMedCrossRef

29.

Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H et al (2010) Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol 82(4):684–691PubMedCrossRef

30.

Hann HW (2010) Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother 11(13):2243–2249PubMedCrossRef

31.

Huang YW, Chayama K, Tsuge M, Takahashi S, Hatakeyama T, Abe H et al (2010) Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic. Antivir Ther 15(2):177–184PubMedCrossRef

32.

Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A et al (2008) Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 48(3):759–769PubMedCrossRef

Titel: Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients
verfasst von: T. D. Shi
J. M. Zhang
X. F. Wang
M. Chen
H. Sun
C. B. Chen
H. Ren
Publikationsdatum: 01.06.2012
Verlag: Springer Milan
Erschienen in: Clinical and Experimental Medicine / Ausgabe 2/2012
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-011-0151-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells

Association of a common variant in TCF7L2 gene with type 2 diabetes mellitus in a Persian population

Angiogenesis in unknown primary tumors

Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors

Detection methods of ZAP-70 in chronic lymphocytic leukemia

Serum peptidome profiling in patients with gastric cancer

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin